Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2016-05-04 Capital/Financing Update
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses an At Market Issuance Sales Agreement for issuing shares up to $50 million, which is a financing activity. There are no financial statements or detailed financial analysis included, just a description of the sales agreement and a legal opinion exhibit. The document length is short (2990 characters), and it is not an annual or quarterly report, nor a call transcript or management discussion. The primary focus is on a capital raising arrangement. Therefore, the document fits best under Capital/Financing Update (CAP).
2016-05-04 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering. It includes detailed information about the terms of the offering, use of proceeds, risk factors, plan of distribution, and legal matters. The document is clearly a capital raising disclosure and not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is not a mere announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2016-05-04 English
Regulatory Filings 2016
Regulatory Filings
2016-04-28 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 26, 2016, by MannKind Corporation. The key content is the announcement of entering into an At Market Issuance Sales Agreement with FBR Capital Markets & Co. for the potential sale of up to $50 million of common stock. This is a clear update on the company's capital raising activities and financing arrangements. There are no financial statements or earnings data presented, nor is this a report of voting results, management changes, or legal proceedings. The document is not a report publication announcement but a current report on a material definitive agreement related to financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing agreement, supporting a high confidence score.
2016-04-26 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from MannKind Corporation to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and discusses procedural aspects of the filing becoming effective. There is no financial data, report content, or detailed disclosures typical of financial reports. The document is short (1881 characters) and serves as a formal request related to a regulatory filing process rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2016-04-26 English
Regulatory Filings 2016
Regulatory Filings
2016-04-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.